4th Conference of the Global Bioequivalence Harmonization Initiative (GBHI)
The fourth conference of the GBHI meeting series was held on December 12 - 13, 2019 in Bethesda, USA.
The main topics of the conference included:
Outcome Summary and Tying Up Loose Ends of GBHI Conference 2018 in Amsterdam
Evaluation of Bioequivalence for Long Acting Injectables and Implants
Necessity of Assessing Bioequivalence for Immediate Release Dosage Forms in the Fed and/or Fasted State
Bioequivalence Assessment of Orally Inhaled Drug Products (OIDPs)
Here you can download the final version of the program.
The scientific and planning committee members:
| Mehul Mehta, US-FDA, Washington, USA (Chair) | Andreas Kovar, Sanofi, Frankfurt, Germany |
| Henning Blume, SocraTec C&S, Oberursel, Germany (Chair) | Henrike Potthast, BfArM, Bonn, Germany |
| Angelica Dorantes, US-FDA, Silver Spring, USA | Barbara Schug, SocraTec R&D, Oberursel, Germany |
| Gerald Beuerle, Teva - Ratiopharm, Ulm/Germany | Anne Seidlitz, University Greifswald, Germany |
| Georg Hempel, University Münster, Germany | Nilufer Tampal, US-FDA, Silver Spring, USA |
| Wenlei Jiang, US-FDA, Silver Spring, USA | |
| Gustavo Mendes Lima Santos, ANVISA, Brazil | Jan Welink, MEB, Utrecht, The Netherlands |
Conference Report
The conference report was published at the European Journal of Pharmaceutical Sciences (Eur J Pharm Sci) in December 2021. Here you can download the article: